Int. J. Mol. Sci. 2013, 14, 1443-1454; doi:10.3390/ijms14011443
International Journal of
Quantitative Structure-Activity Relationships Predicting the
Antioxidant Potency of 17β-Estradiol-Related Polycyclic
Phenols to Inhibit Lipid Peroxidation
Laszlo Prokai 1,*, Nilka M. Rivera-Portalatin 1,† and Katalin Prokai-Tatrai 2
1 Department of Molecular Biology and Immunology, University of North Texas Health Science Center,
Fort Worth, TX 76107, USA; E-Mail: email@example.com
2 Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North
Texas Health Science Center, Fort Worth, TX 76107, USA; E-Mail: firstname.lastname@example.org
† Current address: Department of Chemistry, University of Puerto Rico, Mayagüez, PR 00681,
* Author to whom correspondence should be addressed; E-Mail: email@example.com;
Tel.: +1-817-735-2206; Fax: +1-817-735-2118.
Received: 13 December 2012; in revised form: 3 January 2013 / Accepted: 5 January 2013 /
Published: 11 January 2013
Abstract: The antioxidant potency of 17β-estradiol and related polycyclic phenols has
been well established. This property is an important component of the complex events by
which these types of agents are capable to protect neurons against the detrimental
consequences of oxidative stress. In order to relate their molecular structure and properties
with their capacity to inhibit lipid peroxidation, a marker of oxidative stress, quantitative
structure-activity relationship (QSAR) studies were conducted. The inhibition of
Fe3+-induced lipid peroxidation in rat brain homogenate, measured through an assay
detecting thiobarbituric acid reactive substances for about seventy compounds were
correlated with various molecular descriptors. We found that lipophilicity (modeled by the
logarithm of the n-octanol/water partition coefficient, logP) was the property that
influenced most profoundly the potency of these compounds to inhibit lipid peroxidation in
the biological medium studied. Additionally, the important contribution of the bond
dissociation enthalpy of the phenolic O–H group, a shape index, the solvent-accessible
surface area and the energy required to remove an electron from the highest occupied
molecular orbital were also confirmed. Several QSAR equations were validated as
potentially useful exploratory tools for identifying or designing novel phenolic antioxidants
Int. J. Mol. Sci. 2013, 14
incorporating the structural backbone of 17β-estradiol to assist therapy development
against oxidative stress-associated neurodegeneration.
Keywords: 17β-estradiol; estrogens; lipid peroxidation; phenolic antioxidant; oxidative stress;
Oxidative stress (OS) has been implicated as a key factor to the initiation and/or progression of
numerous pathological processes and premature aging . OS-initiated lipid peroxidation (LPO) has
been extensively studied as a potential biomarker for this detrimental process, since lipids are
particularly sensitive to OS [2,3]. The high unsaturated lipid content of the brain, coupled with high
oxygen utilization, elevated redox-active metal ions concentration and relatively poor antioxidant
defense, makes this organ quite vulnerable to this process and the associated pathologies . One of
the most promising approaches to combat OS and, thus, prevent the resultant LPO is the use of
antioxidants that can either “catch” free radicals or chelate excessive redox metals that can provoke OS
via the formation of reactive oxygen species (ROS) .
Estrogens are unique among steroids in terms of having the phenolic A-ring that allows for eliciting
antioxidant activity similar to that of simple phenolic antioxidants, such as vitamin E or butylated
hydroxytoluene [6,7]. It has become evident that the ability of 17β-estradiol (E2, 1), the main human
estrogen (Figure 1), to act as a direct free radical scavenging antioxidant is an important element in the
cascade of neuroprotective events by which E2 provides protection against OS both in vitro [7–9] and
in vivo [10–12], although the latter is not without controversy . Nevertheless, it has been shown
that E2 and related compounds are able to directly scavenge free radicals and, thereby, alleviate OS
independently of nuclear estrogen receptor (ER) activation [14,15]. Only the free phenolic OH of the
A-ring is the prerequisite for this activity. This seminal finding was first recognized by Behl et al. .
An important new antioxidant cycle for estrogens to shield against free radicals was recently
discovered showing that estrogens can actually be regenerated after sweeping up free radicals [10,17].
Additional proposed mechanisms include the synergistic interaction between estrogens and
glutathione , as well as chelating redox metals, particularly by estrogens having an unsaturated
B-ring . It should also be noted that the indirect antioxidant actions of these biomolecules have
also been confirmed; most prominently via the upregulation of the endogenous antioxidant defense
There are several caveats associated with the use of E2 for antioxidant therapy targeting the brain;
for example, E2 lacks adequate oral bioavailability  and its administration also produces unwanted
hormonal and other potentially detrimental side-effects in the periphery [22,23]. In the search for new
E2-derived agents that preserve E2’s strong antioxidant property  without peripheral liability,
studies with limited scopes have been conducted with E2 derivatives exhibiting diminished or no ER
binding affinity . It has been known that manipulation of ER-binding can be done by introducing
substituents to and/or performing isomerization on the E2 structure [26,27]. In particular, the
fundamental work of Miller et al. concluded that the ER-binding affinity (i.e., estrogenic activity) and
Int. J. Mol. Sci. 2013, 14
antioxidant efficacy can be largely separated with the presence of bulky substituents on the phenolic
A-ring of E2 . Quantitative structure–activity relationship (QSAR) studies connecting the estrogen
structure and ER-binding ability necessary to trigger the well-documented genomic actions of
estrogens have been reported, most particularly to identify estrogenic endocrine disruptors [28–30].
In vitro studies to establish the structural requirements for antioxidant potency have used
small libraries of compounds [15,31,32]. In order to facilitate drug discovery-driven efforts to search
and identify potentially useful antioxidants using E2 and estrone (E1, 2) as templates (Figure 1), we
aimed at performing QSAR studies using an extended library of E2 and E1 derivatives or analogues
(3–60), as well as related polycyclic phenols (61–70). The QSAR modeling was based on the
construction of predictive models for the inhibition of Fe3+-induced LPO in rat brain homogenate by
these compounds , assessed through the detection of thiobarbituric acid reactive substances
(TBARS), as an experimental measure for antioxidant potency. The TBARS assay is a widely adopted
and sensitive method for measuring the extent of LPO . The oxidation of unsaturated fatty acids
leads to the formation of malondialdehyde (MDA) as a breakdown product . The reaction of MDA
with thiobarbituric acid (TBA) produces a pink chromogen when heated at low pH with a typical
maximum absorbance at 532 nm . The MDA-TBA complex measured by the TBARS assay is
considered a gauge for lipid peroxide (LOOH) formation . Based on this established experimental
model, the goal of the present work was to find QSARs that could approximate through a theoretical
approach whether a particular estrogen derivative or related phenolic compound would be a more or
less potent antioxidant against LPO than E2 (1). These models then may serve as exploratory tools for
identifying and designing novel phenolic antioxidants via utilizing the structural backbone of the
Figure 1. Chemical structure of the 17β-estradiol (E2) and estrone (E1).
2. Results and Discussion
2.1. Construction of QSAR Models
The experimental antioxidant potencies, expressed as IC50 values for the inhibition of LPO
measured via the TBARS assay in ovariectomized (OVX) rat brain homogenate against Fe3+-induced
LPO [25,37,38], of the selected compounds (1–70) are given in the Supplementary Information
(Table S1, which is a spreadsheet in Microsoft Excel format also displaying the chemical structures).
Specifically, IC50 of a compound represents the concentration that inhibits 50% of LPO; thus, a smaller
number represents a higher potency in this regard. In comparison with alternative chemometric and
cheminformatics tools, the advantage of a descriptor-based approach for the development of predictive
Int. J. Mol. Sci. 2013, 14
QSAR models focusing on LPO inhibitory activity has been shown recently . Therefore, we
applied the latter strategy to pursue our computational study reported here. The negative logarithm of
the IC50 value (in molar concentration, M) was chosen as the dependent variable, and various
descriptors of the test compounds available through the Project Leader module of the CAChe software
were considered as independent variables for the creation of QSAR models:
−log(IC50-TBARS) = 13.6 (±3.4) − 0.179 (±0.042)BDE (r = 0.46, F = 18.11, p < 0.001)(1)
−log(IC50-TBARS) = −2.69 (±0.36) + 0.118 (±0.021)SIκ1 (r = 0.55, F = 29.85)
−log (IC50-TBARS) = −3.03 (±0.41) + 0.00728 (±0.0031)SA (r = 0.56, F = 30.97) (3)
−log(IC50-TBARS) = −2.27 (±0.27) + 0.295 (±0.052)logP (r = 0.57, F = 32.42) (4)
−log(IC50-TBARS) = 6.48 (±3.42) + 0.237 (±0.0547)logP − 0.105 (±0.041)BDE
(r = 0.58, F = 20.83)
−log(IC50-TBARS) = 6.23 (±2.63) + 0.288 (±0.048)logP + 0.988 (±0.304)HOMO
(r = 0.64, F = 23.78)
−log(IC50-TBARS) = 2.56 (±0.36) + 0.186 (±0.102)logP + 0.0522 (±0.0421)SIκ1
(r = 0.58, F = 17.10)
−log(IC50-TBARS) = 18.5 (±4.3) + 0.209 (±0.050) logP − 0.130 (±0.037)BDE +
1.16 (±0.29)HOMO (r = 0.71, F = 22.60)
The best statistical models are shown in Equations 1–8. We believe that the somewhat modest
correlations were due to the combination of limited structural diversity in the training set and confines
of the in vitro experimental procedure relying on an actual, heterogeneous biological medium 
rather than a well-defined chemical model for LPO . Nevertheless, all of them satisfied the
requirement for statistical significance with p < 0.001 from analysis of variance (ANOVA). The values
of phenolic O–H’s bond dissociation enthalpy (BDE, kcal/mol), a shape index (κ-type, first order,
SIκ1), the solvent-accessible surface area (SA, Å2), lipophilicity (expressed as the logarithm of the
n-octanol/water partition coefficient; logP), and the eigenvalues of a frontier orbital (HOMO, eV) were
the descriptors present in the QSAR models obtained, and these descriptors were also included in
The first four equations represent models created from the use of only a single molecular descriptor.
Equation 4 provided the largest F-value (the ratio of the model’s explained variance to its unexplained
variance, considering F of 15 as threshold value for model selection). This indicated that logP (i.e., a
descriptor related to lipophilicity) had the best predictive value among parameters found to give the
best one-descriptor Equations (1–4; BDE, SIκ1, SA and logP), confirming thereby the previously
established significance of lipophilicity regarding LPO inhibition . In addition, logP was a steady
descriptor included, when equations of acceptable statistical significance were searched using two or
more independent variables, while other variables in these QSAR models were either BDE
(Equation 5), HOMO (Equation 6), SIκ1 (Equation 7), or BDE and HOMO (Equation 8), respectively.
Int. J. Mol. Sci. 2013, 14
Altogether, inclusion of descriptors other than logP in Equations 5–8 decreased the F-values but, with
the exception of including SIκ1 (Equation 7), improved correlation (i.e., increased the r value).
The extended spin distribution in the phenoxyl radical (ArO•) derived from the parent phenolic
antioxidant (ArOH; e.g., E2) after it donates its H from the phenolic OH to a free radical to terminate
the propagation of a radical reaction has been suggested to be an important contributor for the radical
scavenging activity [41,42]. A smaller value of this parameter projects a more stable ArO• and,
consequently, better antioxidant potency . Nevertheless, correlation of BDE with extended spin
distribution, as well as with the enthalpy of single-electron transfer and the ionization potential (IP)
were also noted . Therefore, the BDE was considered for the construction of QSAR models in this
context. The BDE increases with the increasing electron withdrawal by the substituents surrounding
ArOH; in other words, O–H bond is weakened by increasing the electron density and strengthened by
decreasing the electron density within the bond . Accordingly, electron donating group(s) on the
A-ring of an estrogen should positively impact the antioxidant potency compared to that of the
unsubstituted E2 (1). Concurring, Equations 1, 5 and 8 correctly predict that the inhibition of LPO
decreases with increasing BDE. This tendency is expected, because compounds that can easily donate
the hydrogen of the phenolic OH to break the cascade of radical-mediated reactions are those with low
BDE. This process is schematically shown in Figure 2 ; where LH represents a lipid molecule,
LOO• is the product of a very fast O2-addition to the chain initiator  formed by the reaction
LH L• upon the attack by ROS, and LOOH is lipid hydroperoxide. The chain-breaking reaction
ArOH + LOO• ArO• + LOOH prevents LPO cycle propagated by an H-atom exchange reaction
(LOO• + LH LOOH + L•) that regenerates the chain initiator. The pathway drawn in red represent
the actual chain-breaking H-atom transfer, while the blue portion of Figure 2 implicates the conversion
of the phenoxyl radical (ArO•) back to the phenolic compound (ArOH) by an endogenous reductant
AH such as ascorbate, which is converted to its oxidized form A’ in the process .
Figure 2. Schematic illustration of lipid peroxidation (LPO) inhibition by phenolic antioxidants.
Int. J. Mol. Sci. 2013, 14
The HOMO energy (the energy required to remove an electron from the highest occupied molecular
orbital) has also been connected to the ability of a phenolic compound to donate electrons to free
radicals. According to Koopman’s theorem and the molecular orbital theory , it determines the IP.
Therefore, the involvement of the HOMO energy as descriptor refining two different QSAR models
(Equations 6 and 8, respectively) was not unexpected, although it did not qualify alone to be among the
one-parameter equations giving statistically acceptable correlation. Nevertheless, it was noticeable that
correlation increased when this descriptor was also used in the two-parameter equations in addition to
logP and BDE, respectively. It is noteworthy that the best three-parameter equation also included
HOMO (Equation 8) and, provided a larger r-value than BDE and logP without this descriptor
(Equation 5). The influence of a topological index related to the shape of a molecule was also revealed.
The SIκ1 quantifies the number of cycles in the compound [46,47]. Equations 2 and 7 predict that a
large SIκ1 value improves the antioxidant potency of an E2-related polycyclic phenol. SA also gave a
good correlation and had apparent descriptive value considering the TBARS assay as a measure of
LPO inhibition by these compounds. These descriptors were calculated at an optimized geometry in
water using the conductor-like screening model (COSMO) for solvation . Equation 3 suggests that
a higher antioxidant activity could be obtained with molecules having a higher SA.
2.2. Validation of QSAR Models (Equations 1–8)
An important step in the QSAR modeling is to validate the obtained models. An initial validation
was carried out for the best models (Equations 1–8) through randomly leaving out 10% of compounds
from the training set [49,50] (data not shown). The equations fitted to this reduced training set with the
same descriptors yielded slightly different regression coefficients, but the correlation coefficients of
the equations remained similar to those obtained with all entities (1–70) included. In addition, the lack
of chance correlations in the reported QSAR models was also ensured by analyzing the equations after
randomization of the experimental values.
In a more rigorous validation that was independent from our training set, the obtained QSAR
equations were used to predict the relative antioxidant potencies of A-ring substituted estrogens and
compared with those obtained by Badeau et al. . These authors analyzed a group of estrogens for
their antioxidant capacity and reported the potencies of the compounds as more active or less active
than E2 (1). The IC50’s for the TBARS of these compounds were predicted using QSAR Equations 1–8
and compared with the results reported. The validity of the predictions was determined based on the
number of false positives (compounds that were less potent than E2 but were predicted to be more
potent), false negatives (compounds that are more potent than E2 but were predicted to be less potent)
and well-predicted compounds (Table 1). Even though the experimental approach by
Badeau et al.  was not based on the TBARS method but assessed the antioxidant effect on
copper-induced oxidation of lipoproteins through the continuous monitoring of conjugated diene
formation, our QSAR Equations 1 and 4–8 still correctly predicted the relative antioxidant capacities
of A-ring substituted estrogens. Therefore, the strong influence of logP, as well as the contribution of
BDE, SIκ1 and HOMO was certainly confirmed in a general context of LPO inhibition by these
Int. J. Mol. Sci. 2013, 14
Table 1. QSAR model validation using data reported by Badeau et al. ).
False Positives a
False Negatives b
Correctly Predicted c
a False positives are compounds that are less potent than E2 but were predicted to be more potent; b False
negatives are those compounds that are more potent than E2 but were predicted to be less potent; and
c Correctly-predicted are those compounds that were predicted correctly as more or less potent than E2 .
Leaving out Equations 2 and 3 that were definitely not validated by this strategy, the overall rate of correct
predictions was 74%, while false positives and false negatives were 16% and 10%, respectively.
3. Experimental Section
3.1. Materials and Methods
Triton X-100, EDTA, bovin serum albumin (BSA), copper (II) sulfate, bicinchoninic acid (BCA),
iron (III) chloride, trichloroacetic acid, hydrochloric acid and thiobarbituric acid (TBA) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and solvents were
purchased from Fisher Scientific Company (Pittsburgh, PA, USA). Brains were obtained from 2 to
6 ovariectomized (OVX) Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA, USA),
three weeks after ovariectomy to ensure that endogenous E2 and E1 would be negligible in the animals
and, therefore, would not be interfering factors in the in vitro studies. All animal procedures were
approved by the Animal Care and Use Committee of University of North Texas Health Science Center.
The training data set used to construct the models for the QSAR study was composed of
seventy compounds. These compounds were commercially available (Steraloids, Newport, RI or
Sigma-Aldrich, St. Louis, MO, USA), or their availability has been specified earlier . They are
listed in Table S1, along with their experimentally determined antioxidant potencies against
iron(III)-induced LPO in OVX rat brain homogenate expressed as IC50 values (in molar concentration,
M) relying on the TBARS method [25,37]. Protein concentrations were determined through
bicinchoninic acid assay [51,52]. Briefly, 20% w/v rat brain homogenate  (prepared in
aqueous TritonX buffer: TritonX-100, 1% v/v; EDTA 1 mM; NaCl, 0.9% w/v) was diluted into
phosphate-buffered saline, pH 7.4, to afford 1 mg/mL protein concentration. After addition of the test
compound from ethanolic stock solution, the mixture was held at room temperature for 30 min. FeCl3
was then added from aqueous stock solution to reach 300 µM in its concentration, and the sample was
incubated at 37 °C for 15 min. For the measurement of MDA formation, 150 µL of 12.5% (v/v)
trichloroacetic acid in 0.8 N HCl and 300 µL TBA (1%, w/v) solutions were added and incubated for
an additional hour at 37 °C. Then, the sample was centrifuged at 12,000 rpm for 2 min. The relative
fluorescent units (RFU) of the supernatant was determined at an excitation and emission wavelengths
Int. J. Mol. Sci. 2013, 14
of 530 and 590 nm respectively in a fluorescence FL600 microplate reader (Biotek, Winooski, VT,
USA). The percent of inhibition of LPO from the TBAR assay was calculated as follows:
% inhibition = (1 − A/A0) × 100 (9)
where A is the absorbance in the presence of the antioxidant compound at various concentrations and
A0 is the absorbance of the control reaction. Each compound was tested in three independent
experiments with five to six different levels of inhibitor concentration in each experiment. Sigmoidal
dose–response relationships were presumed. Prism (version 3.0; GraphPad Software, La Jolla, CA,
USA, 2005) was used to calculate the IC50 values of the compounds.
Computations were performed by using CAChe software (version 6.1.1; Fujitsu, Beaverton, OR,
USA, 2006). Structures were preoptimized using augmented MM3 parameters followed by full
geometry optimization (RMS gradient <0.1 kcal/(Å·mol)) and energy minimization by using the PM5
semi-empirical method with open-shell wave functions (unrestricted Hartree-Fock (UHF) approach).
QSAR equations were obtained through the Project Leader molecular spreadsheet linked to CAChe.
In addition to “built-in” structural, spatial, electronic, quantum-chemical and thermodynamic
descriptors available through this module, BDE of the phenolic O–H bond  was also included for
each compound. The latter descriptor was calculated as
BDE = Hr + HH − Hp (10)
where Hp and Hr were the calculated enthalpies of formation for the parent phenolic molecule and for
the phenoxyl radical, respectively, while an experimental value (52.08 kcal/mol) was used as the
enthalpy of formation for the hydrogen atom (HH). The stepwise regression algorithm of the Project
Leader module was applied to select appropriate descriptors for building the QSAR models. ANOVA
was performed using the Minitab software (version 14; Minitab Inc., State College, PA, USA, 2005) to
obtain the F-values for the regressions.
The main finding of our QSAR study reported here is that lipophilicity was the property that
influenced most profoundly the potency of estrogen derivatives and related polycyclic phenols to
inhibit iron(III)-induced LPO in rat brain homogenate. The contribution of BDE of the phenolic O–H
group, a shape index (SIκ1) and HOMO was also confirmed by our theoretical approach. Several
QSAR Equations 1 and 4–8 were validated as potentially useful exploratory tools for identifying or
designing novel phenolic antioxidants incorporating the structural backbone of E2 to inhibit LPO and,
thus, to assist the discovery of potential therapeutic interventions that could alleviate oxidative
stress-induced neurodegeneration in the brain.
This work was supported by the National Institute of Health (grant numbers NS044765 and
AG031535 to L.P.) and the Robert A. Welch Foundation (endowment number BK-0031 to L.P.). The
Int. J. Mol. Sci. 2013, 14
authors acknowledge the permission of J.W. Simpkins for the use of his laboratory and also for
providing technical support to N.M.R.-P. who performed the TBARS assays that enabled the inclusion
of several estrogen derivatives with previously not reported antioxidant potencies into our QSAR study.
We thank Alexander Oliferenko for the critical reading of and valuable comments on the manuscript.
Conflict of Interest
The authors declare no conflict of interest.
1. Mariani, E.; Polidori, M.C.; Cherubini, A.; Mecocci, P. Oxidative stress in brain aging,
neurodegenerative and vascular diseases: An overview. J. Chromatogr. B 2005, 827, 65–75.
2. Niki, E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors 2008, 34,
3. Wagner, B.A.; Buettner, G.R.; Burns, C.P. Free radical-mediated lipid peroxidation in cells:
Oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry 1995, 33,
4. Butterfield, D.A.; Lange, M.L.B.; Sultana, R. Involvements of the lipid peroxidation product,
HNE, in the pathogenesis and progression of Alzheimer’s disease. Biochim. Biophys. Acta 2010,
5. Mancuso, C.; Barone, E.; Guido, P.; Miceli, F.; Di Domenico, F.; Perluigi, M.; Santangelo, R.;
Preziosi, P. Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous
antioxidants in rat brain microsomes in vitro. Neurosci. Lett. 2012, 19, 101–105.
6. Mooradian, A.D. Antioxidant properties of steroids. J. Steroid Biochem. Mol. Biol. 1993, 45,
7. Prokai-Tatrai, K.; Prokai, L.; Jung, M.E. Phenolic compounds protect cultured hippocampal
neurons against ethanol-withdrawal induced oxidative stress. Int. J. Mol. Sci. 2009, 10,
8. Siriphorn, A.; Chompoopong, S.; Floyd, C.L. 17β-estradiol protects Schwann cells against
H2O2-induced cytotoxicity and increases transplanted Schwann cell survival in a cervical
hemicontusion spinal cord injury model. J. Neurochem. 2010, 115, 864–872.
9. Wilson, M.E.; Dubal, D.B.; Wise, P.M. Estradiol protects against injury-induced cell death in
cortical explant cultures: A role for estrogen receptors. Brain Res. 2000, 873, 235–242.
10. Prokai, L.; Prokai-Tatrai, K.; Perjesi, P.; Zharikova, A.D.; Perez, E.J.; Liu, R.; Simpkins, J.W.
Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc. Nat. Acad. Sci. USA
2003, 96, 8867–8872.
11. Gerstner, B.; Lee, J.; DeSilva, T.M.; Jensen, F.E.; Volpe, J.J.; Rosenberg, P.A. 17beta-estradiol
protects against hypoxic/ischemic white matter damage in the neonatal rat brain. J. Neurosci. Res.
2009, 87, 2078–2086.
12. Kii, N.; Adachi, N.; Liu, K.; Arai, T. Acute effects of 17beta-estradiol on oxidative stress in
ischemic rat striatum. J. Neurosurg. Anesthesiol. 2005, 17, 27–32.
Int. J. Mol. Sci. 2013, 14
13. Strom, J.O.; Theodorsson, A.; Theodorsson, E. Dose-related neuroprotective versus
neurodamaging effects of estrogens in rat cerebral ischemia: A systematic analysis. J. Cereb.
Blood Flow Metabol. 2009, 29, 1359–1372.
14. Prokai, L.; Oon, S.M.; Prokai-Tatrai, K.; Abboud, K.A.; Simpkins, J.W. Synthesis and biological
evaluation of 17beta-alkoxyestra-1,3,5(10)-trienes as potential neuroprotectants against oxidative
stress. J. Med. Chem. 2001, 4, 110–114.
15. Prokai, L.; Simpkins, J.W. Structure-nongenomic neuroprotection relationship of estrogens and
estrogen-derived compounds. J. Pharmacol. Ther. 2007, 114, 1–12.
16. Moosmann, B.; Behl, C. The antioxidant neuroprotective effects of estrogens and phenolic
compounds are independent from their estrogenic properties. Proc. Natl. Acad. Sci. USA 1999, 96,
17. Prokai-Tatrai, K.; Perjesi, P.; Rivera-Portalatin, N.M.; Prokai, L. Mechanistic investigations on
the antioxidant action of a neuroprotective estrogen derivative. Steroids 2009, 73, 280–288.
18. Hum, P.D.; Macrae, M. Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow Metabol
2000, 2, 631–652.
19. Römer, W.; Oettel, M.; Menzenbach, B.; Droescher, P.; Schwarz, S. Novel estrogens and their
radical scavenging effects, iron-chelating, and total antioxidative activities: 17-alpha-substituted
analogs of delta 9(11)-dehydro-17 beta-estradiol. Steroids 1997, 62, 688–694.
20. Yune, T.E.; Kim, S.J.; Lee, S.M.; Lee, Y.K.; Oh, Y.J.; Kim, Y.C.; Markelonis, G.J.; Oh, T.H.
Systemic administration of 17b-estradiol reduces apoptotic cell death and improves functional
recovery following traumatic spinal cord injury in rats. J. Neurotrauma 2004, 21, 293–306.
21. Wu, B.; Kulkarni, K.; Basu, S.; Zhang, S.; Hu, M. First-pass metabolism via
UDP-glucuronosyltransferase: A barrier to oral bioavailability of phenolics. J. Pharm. Sci. 2011,
22. DePaolo, L.; Negro-Vilar, A. Estrogenic feminization of the LH response to orchidectomy in the
rat: Evidence for a hypothalamic site of action. Neuroendocrinol 1982, 34, 104–111.
23. Hsueh, A.J.W.; Peck, E.J.; Clark, J.H. Progesterone antagonism of the oestrogen receptor and
oestrogen-induced uterine growth. Nature 1975, 254, 337–339.
24. Ruiz-Larrea, M.B.; Martin, C.; Martinez, R.; Navarro, R.; Lacort, M.; Miller, N.J. Antioxidant
activities of estrogens against aqueous and lipophilic radicals; differences between phenol and
catechol estrogens. Chem. Phys. Lipids 2000, 105, 179–188.
25. Perez, E.; Cai, Z.Y.; Covey, D.F.; Simpkins, J.F. Neuroprotective effects of estratriene analogs:
Structure-activity relationships and molecular optimization. Drug Dev. Res. 2005, 66, 78–92.
26. Cummins, C.H. Synthesis and radiochemistry of 2,4-disubstituted 17-iodovinylestradiols. Steroids
1994, 59, 590–596.
27. Miller, C.P.; Jirkovsky, I.; Hayhurst, D.A.; Adelmant, S.J. In vitro antioxidant effects of estrogens
with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein.
Steroids 1996, 61, 305–308.
28. Tong, W.; Perkins, R.; Strelitz, R.; Collantes, E.R.; Keenan, S.; Welsh, W.J.; Branham, W.S.;
Sheehan, D.M. Quantitative structure-activity relationships (QSARs) for estrogen binding to the
estrogen receptor: predictions across species. Environ. Health Perspect. 1997, 105, 1116–1124.
Int. J. Mol. Sci. 2013, 14
29. Hu, J.-Y.; Aizawa, T. Quantitative structure-activity relationships for estrogen receptor binding
affinity of phenolic chemicals. Water Res. 2003, 37, 1213–1222.
30. Hong, H.; Tong, W.; Fang, H.; Shi, L.; Xie, Q.; Wu, J.; Perkins, R.; Walker, J.D.; Branham, W.;
Sheehan, D.M. Prediction of estrogen receptor binding for 58,000 chemicals using an integrated
system of a tree-based model with structural alerts. Environ. Health Perspect. 2002, 110, 29–36.
31. Behl, C.; Skutella, T.; Lezoualc’h, F.; Post, A.; Widmann, M.; Newton, C.J.; Holsboer, F.
Neuroprotection against oxidative stress by estrogens: Structure-activity relationship.
Mol. Pharmacol. 1997, 51, 535–541.
32. Badeau, M.; Adlercreutz, H.; Kaihocaara, P.; Tikkanen, M.J. Estrogen A-ring structure and
antioxidative effect on lipoproteins, J. Steroid Biochem. Mol. Biol. 2005, 96, 271–278.
33. Callaway, J.K.; Beart, P.M.; Jarrott, B. A reliable procedure for comparison of antioxidants in rat
brain homogenates. J. Pharmacol. Toxicol. Meth. 1998, 39, 155–162.
34. Esterbauer, H.; Cheeseman, K.H. Determination of aldehydic lipid peroxidation products:
Malondialdehyde and 4-hydroxynonenal. Methods Enzymol. 1990, 186, 407–421.
35. Mihaljevic, B.A.; Katusin-Razem, B.; Razem, D. The reevaluation of the ferric thiocyanate assay
for lipid hydroperoxides with special considerations of the mechanistic aspects of the response.
Free Radic. Biol. Med. 1996, 21, 53–63.
36. Janero, D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid
peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 1990, 9, 515–540.
37. Rivera-Portalatin, N.M. Mechanism of the Antioxidant Action of Estrogens. Ph.D. Thesis,
University of Florida, Gainesville, FL, USA, 2006.
38. Perez, E.J. Estratriene Neuroprotection through Antioxidant, Non-Estrogen Receptor Mediated
Mechanisms. Ph.D. Thesis, University of Florida, Gainesville, FL, USA, 2004, p. 102.
39. Mitra, I.; Saha, A.; Roy, K. In silico development, validation and comparison of predictive QSAR
models for lipid peroxidation inhibitory activity of cinnamic acid and caffeic acid derivatives
using multiple chemometric and cheminformatics tools. J. Mol. Model. 2012, 18, 3951–3967.
40. Cheng, Z.Y.; Ren, J.; Li, Y.Z.; Chang, W.B.; Chen, Z.D. Establishment of a quantitative
structure-activity relationship model for evaluating and predicting the protective potentials of
phenolic antioxidants on lipid peroxidation. J. Pharm. Sci. 2003, 92, 475–484.
41. Bakalbassis, E.G.; Chatzopoulou, A.; Malissas, V.S.; Tsimidou, M.; Vafiadis, A. Ab initio and
density functional theory studies for the explanation of the antioxidant activity of certain phenolic
acids. Lipids 2001, 36, 181–190.
42. Mukai, K.; Uemoto, Y.; Fukuhara, M.; Nagaoka, S.; Ishizu, K. ENDOR study of the cation
radicals of vitamin-E derivatives-relation between antioxidant activity and molecular-structure.
Bull. Chem. Soc. Jpn. 1992, 65, 2016–2020.
43. Bordwell, F.G.; Zhang, X.-M.; Satish, A.V.; Cheng J.-P. Assessment of the importance of
changes in ground-state energies on the bond dissociation enthalpies of the O–H bonds in phenols
and the S–H bonds in thiophenols. J. Am. Chem. Soc. 1994, 116, 6605–6610.
44. Prokai, L.; Prokai-Tatrai, K.; Perjesi, P.; Simpkins, J.W. Mechanistic insights into the direct
antioxidant effects of estrogens. Drug Dev. Res. 2006, 66, 118–125.
Int. J. Mol. Sci. 2013, 14
45. Pedulli, G.F.; Lucarini, A.; Pedrielli, P. Bond Dissociation Energies of Phenolic and Amine
Antioxidants. In Free Radicals in Biology and Environment; Minisci, F., Ed.; Kluwer Academic
Publishers: Dordrecht, The Netherland, 1997; pp. 169–180.
46. Kier, L.B. Indexes of molecular shape from chemical graphs. Med. Res. Rev. 1987, 7, 417–440.
47. Katritzky, A.R.; Gordeeva, E.V. Traditional topological indices vs. electronic, geometric,
combined molecular descriptors in QSAR/QSPR research, J. Chem. Inf. Comput. Sci. 1993, 33,
48. Klamt, A.; Schüürmann, G. COSMO: A new approach to dielectric screening in solvents with
explicit expressions for the screening energy and its gradient. J. Chem. Soc. Perkin Trans. 1993,
49. Lorand, T.; Kocsis, B.; Sohar, P.; Nagy, G.; Jozsef, P.; Kispal, G.; Laszlo, R. Prokai, L. Synthesis
and antibacterial effect of fused Mannich ketones. Eur. J. Med. Chem. 2002, 37, 803–812.
50. Kocsis, B.; Kustos, I.; Kilar, F.; Nyul, A.; Jakus, P.B.; Kerekes, S.; Villarreal, V.; Prokai, L.;
Lorand, T. Antifungal unsaturated cyclic Mannich ketones and aminoalcohols: Study of
mechanism of action. Eur. J. Med. Chem. 2009, 44, 1823–1829.
51. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.;
Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using
bicinchoninic acid. Anal. Biochem. 1985, 150, 76–85.
52. Walker, J.M. The Bicinchoninic Acid (BCA) Assay for Protein Quantitation. In The Protein
Protocols Handbook, 3rd ed.; Walker, J.M., Ed.; Humana Press: New York, NY. USA, 2009;
53. Nguyen, V.; Zharikova, A.D.; Prokai-Tatrai, K.; Prokai, L. [Glu2]TRH dose-dependently
attenuates TRH-evoked analeptic effect in the mouse brain. Brain Res. Bull. 2010, 82, 83–86.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license